COMPASS Pathways: COMP360 psilocybin therapy shows potential

COMPASS Pathways: COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression

Positive early signals seen in two investigator-initiated studies presented at the Society of Biological Psychiatry Annual Meeting in New Orleans London, UK - 3 May 2022

Related Keywords

United Kingdom , London , City Of , Stephen Schultz , Walter Kaye , Sheppard Pratt , Amy Lawrence , Exchange Commission , Linkedin , Society Of Biological Psychiatry Annual Meeting , Nasdaq , Biological Psychiatry Annual Meeting , New Orleans , Montgomery Asberg Depression Rating Scale , California San Diego School , Securities Act , Private Securities Litigation Reform Act , Compass , Pathways , Omp360 , Silocybin , Therapy , Shows , Potential , Exploratory , Pen , Label , Studies , Anorexia , Nervosa , Evere , Treatment , Resistant , Depression ,